COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,233 Articles (22,733 medRxiv, 8,500 bioRxiv)

Most recent first Previous |  Page 1071: Articles 10701-10710  | Next

Durability of mRNA-1273 against COVID-19 in the time of Delta: Interim results from an observational cohort study
Florea, A., Sy, L. S., Luo, Y., Qian, L., Bruxvoort, K. J., Ackerson, B. K., Lee, G. S., Ku, J. H., Tubert, J. E., Tian, Y., Talarico, C. A., Tseng, H. F.
10.1101/2021.12.13.21267620 — Posted: 2021-12-14
Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection
Nemet, I., Kliker, L., Lustig, Y., Zuckerman, N. S., Cohen, C., Kreiss, Y., Alroy-Preis, S., Regev-Yochay, G., Mendelson, E., Mandelboim, M.
10.1101/2021.12.13.21267670 — Posted: 2021-12-14
The Omicron variant is highly resistant against antibody-mediated neutralization - implications for control of the COVID-19 pandemic
Hoffmann, M., Krüger, N., Schulz, S., Cossmann, A., Rocha, C., Kempf, A., Nehlmeier, I., Graichen, L., Moldenhauer, A.-S., Winkler, M. S., Lier, M., Dopfer-Jablonka, A., Jäck, H.-M., Behrens, G., Pöhlmann, S.
10.1101/2021.12.12.472286 — Posted: 2021-12-13
Inactivation of SARS-CoV-2 and influenza A virus by spraying hypochlorous acid solution and hydrogen peroxide solution in the form of Dry Fog
Urushidani, M., Kawayoshi, A., Kotaki, T., Saeki, K., Mori, Y., Kameoka, M.
10.1101/2021.12.13.472413 — Posted: 2021-12-13
Plasma neutralization properties of the SARS-CoV-2 Omicron variant
Schmidt, F., Muecksch, F., Weisblum, Y., Da Silva, J., Bednarski, E., Cho, A., Wang, Z., Gaebler, C., Caskey, M., Nussenzweig, M., Hatziioannou, T., Bieniasz, P.
10.1101/2021.12.12.21267646 — Posted: 2021-12-13 Discussion: Onsite
Broad antiviral effects of Echinacea purpurea against SARS-CoV-2 variants of concern and potential mechanism of action
Vimalanathan, S., Shehata, M., Sadasivam, K., Delbue, S., Dolci, M., Pariani, E., D'Alessandro, S., Pleschka, S.
10.1101/2021.12.12.472255 — Posted: 2021-12-13
Epistatic models predict mutable sites in SARS-CoV-2 proteins and epitopes
Rodriguez-Rivas, J., Croce, G., Muscat, M., Weigt, M.
10.1101/2021.12.11.472202 — Posted: 2021-12-13
Improved neutralization of the SARS-CoV-2 Omicron variant after Pfizer-BioNTech BNT162b2 COVID-19 vaccine boosting
Basile, K., Rockett, R. J., McPhie, K., Fennell, M., Johnson-Mackinnon, J., Agius, J., Fong, W., Rahman, H., Ko, D., Donavan, L., Hueston, L., Lam, C., Arnott, A., Chen, S., Maddocks, S., O'Sullivan, M., Dwyer, D. E., Sintchenko, V., Kok, J.
10.1101/2021.12.12.472252 — Posted: 2021-12-13
SARS-CoV-2 Spike triggers barrier dysfunction and vascular leak via integrins and TGF-β signaling
Biering, S. B., Tramontini Gomes de Sousa, F., Tjang, L. V., Pahmeier, F., Ruan, R., Blanc, S. F., Patel, T. S., Worthington, C. M., Glasner, D. R., Castillo-Rojas, B., Servellita, V., Lo, N. T., Wong, M. P., Warnes, C. M., Sandoval, D. R., Clausen, T. M., Santos, Y. A., Ortega, V., Aguilar-Carreno, H., Esko, J. D., Chiu, C. Y., Pak, J. E., Beatty, P. R., Harris, E.
10.1101/2021.12.10.472112 — Posted: 2021-12-13
SARS-CoV2 variant-specific replicating RNA vaccines protect from disease and pathology and reduce viral shedding following challenge with heterologous SARS-CoV2 variants of concern
Hawman, D. W., Meade-White, K., Archer, J., Leventhal, S., Wilson, D., Shaia, C., Randall, S., Khandhar, A. P., Hsiang, T.-Y., Gale, M., Berglund, P., Fuller, D. H., Feldmann, H., Erasmus, J.
10.1101/2021.12.10.472134 — Posted: 2021-12-13

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).